Liberum Capital Has Just Reaffirmed GBX 2200.00 Target Price Per Share o

Share

Victrex PLC (LON:VCT) Rating Reaffirmed

Equities researchers at Liberum Capital now has a GBX 2200.00 Estimated Target Price on Victrex PLC (LON:VCT). Liberum Capital and their recent Estimated Target Price suggests a potential upside of 22.09% from the company’s stock close price. The rating has been released in a note on Thursday, 10 December.

From a total of 16 analysts covering Victrex PLC (LON:VCT) stock, 8 rate it a ”Buy”, 1 a “Sell”, and 7 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is GBX 2450 while the lowest target price is GBX 1700. The mean of all analyst targets is GBX 2133 with a 19.42% above today’s (GBX 1796) stock price. Victrex PLC was the topic of 28 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. BNP Paribas maintained shares on December 9 with “Outperform” rating. UBS maintained shares with “Neutral” rating and GBX 2020 target share price in a report from an October 8. Deutsche Bank maintained VCT stock in a recent report from December 9 with “Hold” rating. N+1 Singer maintained the rating on October 8. N+1 Singer has a “Hold” rating and a GBX 2100 price target on shares. Finally, Credit Suisse maintained the stock with “Outperform” rating in a report issued on a November 30.

Approximately 22,410 shares of stock traded hands. Victrex plc (LON:VCT) has declined 11.65% since May 13, 2015 and is downtrending. It has underperformed by 9.72% the S&P500.

Liberum Capital Has Just Reaffirmed GBX 2200.00 Target Price Per Share on Victrex PLC (LON:VCT) stock, While They’ve Also Reiterated Their

Victrex plc is a United Kingdom-based firm engaged in the manufacture of polymer solutions. The company has a market cap of 1.57 billion GBP. The Company’s products are used in smartphones, gas and oil equipment, medical devices, aeroplanes and cars. It has 18.35 P/E ratio. The Firm has activities in industries such as Automotive, Aerospace, Electronics, Energy and Medical.

COMMENTS: